多模态人工智能系统用于风险适配的癌症生存者监测:多中心目标试验模拟
该研究以2148例II期鼻咽癌患者为模型,采用目标试验模拟确认治疗降强度安全,并训练Transformer架构预测个体化治疗失败时间,转化为风险适配监测策略。AI系统内部AUC 0.991、外部验证0.986,使超过90%无失败患者减少随访需求,高危者5年内最多仅需6次随访,对真实失败检测敏感性高。
要点
- 目标试验模拟显示省略同步化疗与同步放化疗生存结局相当,确立安全降强度基线。
- AI系统预测治疗失败时间,内部AUC 0.991、多中心外部验证AUC 0.986。
- AI引导策略使超过90%无失败患者减少随访,高危者5年内最多6次随访。
核心结论
- 多模态AI框架可补充NCCN指南,减少癌症生存者监测负担。
研究设计与样本
- 多中心目标试验模拟,纳入5个中心2148例II期鼻咽癌患者。
- 训练Transformer架构预测个体化治疗失败时间并转化为风险适配监测策略。
主要发现
- 目标试验模拟中省略同步化疗与同步放化疗在所有队列生存结局相当。
- AI系统预测治疗失败内部AUC 0.991,多中心外部验证AUC 0.986。
- AI引导策略使超过90%无失败患者减少随访需求,高危者5年内最多6次随访。
- AI策略对检测真实失败表现出高敏感性。
关键数值与推荐
- AI系统内部AUC 0.991,多中心外部验证队列AUC 0.986。
- 超过90%无失败患者减少随访需求,高危个体5年内最多6次随访。
临床怎么用
- 利用AI预测治疗失败时间,为鼻咽癌生存者制定风险适配随访频率。
- 对高危患者5年内安排最多6次随访,低危无失败患者减少随访。
局限性
- 研究为II期鼻咽癌模型,结论推广至其他癌种需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The growing population of cancer survivors faces immense monitoring burdens because of rigid follow-up guidelines, such as the intensive surveillance schedules recommended by the National Comprehensive Cancer Network. To address this issue, we engineered a multimodal artificial intelligence (AI)-based decision support system that integrates biological domain data (magnetic resonance imaging) and physical treatment domain data (radiation therapy dose maps) to guide individualized care. METHODS AND MATERIALS: Using stage II nasopharyngeal carcinoma (N = 2148 across 5 centers) as a model, we first implemented a target trial emulation framework to confirm the safety of treatment deintensification and establish a baseline for streamlined surveillance. We then trained a transformer architecture to predict individualized treatment failure timing and translated these predictions into a risk-adapted surveillance strategy. RESULTS: In the target trial emulation, omitting concurrent chemotherapy demonstrated comparable survival outcomes with concurrent chemoradiation therapy across all cohorts, establishing a safely deintensified clinical baseline. Subsequently, the AI system achieved high-fidelity predictions, with an area under the curve of 0.991 internally and 0.986 in the multi-institutional external validation cohort. This AI-guided strategy substantially reduced the need for follow-up visits for over 90% of failure-free patients, while recommending a maximum of only 6 visits for high-risk individuals over a 5-year period, demonstrating a high sensitivity for detecting true failures. CONCLUSIONS: This generalizable AI framework can seamlessly complement the current National Comprehensive Cancer Network guidelines, offering a transformative, data-driven solution that reduces the global monitoring burden of cancer survivorship care.
引用
- Zhang LN, Wang YT, Lan XW, et al. Multimodal Artificial Intelligence System for Risk-Adapted Cancer Survivorship Surveillance: A Multicenter Target Trial Emulation. Int J Radiat Oncol Biol Phys. 2026. PMID: 42612835. doi:10.1016/j.ijrobp.2026.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。